Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with ...

Its Herceptin biosimilar nearing launch, Celltrion begins work on Keytruda copySouth Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster ...

Barça Academy, the junior programme associated with internationally recognised football club Barcelona FC, held a week-long experience camp for young football players in both Wellington and Auckland ...

Pharma Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation By Angus Liu Jun 13, 2025 10:50am Merck & Co. Keytruda head and neck cancer PD-1/L1 ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC ...

Nonetheless, though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck is also working on different strategies to drive Keytruda's long-term ...

Key Takeaways Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 ...

Merck is also working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers. Studies found patients taking Keytruda can reduce ...

VIENNA, Va., June 18, 2025--FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine.